KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Liabilities and Shareholders Equity of $215.5 million in Q3 2025, down 14.06% quarter-over-quarter from $250.8 million in Q2 2025, and up 7.65% year-over-year from $200.2 million in Q3 2024.
KalVista Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $215.5 million for Q3 2025.
- In Q3 2025, Liabilities and Shareholders Equity rose 7.65% year-over-year to $215.5 million; the TTM figure through Jul 2025 stood at $921.9 million (up 33.94% YoY), while the FY2025 annual figure was $250.8 million, up 6.53% from the prior year.
- Liabilities and Shareholders Equity came in at $215.5 million for Q3 2025 at KalVista Pharmaceuticals, down from $250.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $294.8 million in Q4 2024 to a low of $66.2 million in Q1 2021.
- A 5-year average of $198.6 million and a median of $203.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity jumped 239.93% in 2022 and tumbled 43.99% in 2024, its largest moves.
- KalVista Pharmaceuticals' Liabilities and Shareholders Equity stood at $243.8 million in 2021, then plunged by 33.21% to $162.8 million in 2022, then fell by 14.8% to $138.7 million in 2023, then soared by 112.49% to $294.8 million in 2024, then retreated by 26.9% to $215.5 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $215.5 million, $250.8 million, and $294.8 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 215.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 215.51 Mn |
| Apr 30, 2025 | 250.77 Mn |
| Dec 31, 2024 | 294.82 Mn |
| Oct 31, 2024 | 160.83 Mn |
| Jul 31, 2024 | 200.20 Mn |
| Apr 30, 2024 | 235.40 Mn |
| Jan 31, 2024 | 113.97 Mn |
| Oct 31, 2023 | 138.74 Mn |
| Jul 31, 2023 | 160.33 Mn |
| Apr 30, 2023 | 183.20 Mn |
| Jan 31, 2023 | 203.47 Mn |
| Oct 31, 2022 | 162.84 Mn |
| Jul 31, 2022 | 182.32 Mn |
| Apr 30, 2022 | 203.88 Mn |
| Jan 31, 2022 | 225.05 Mn |
| Oct 31, 2021 | 243.81 Mn |
| Jul 31, 2021 | 259.13 Mn |
| Apr 30, 2021 | 272.01 Mn |
| Jan 31, 2021 | 66.21 Mn |
| Oct 31, 2020 | 75.45 Mn |
| Jul 31, 2020 | 83.90 Mn |
| Apr 30, 2020 | 92.53 Mn |
| Jan 31, 2020 | 102.94 Mn |
| Oct 31, 2019 | 112.06 Mn |
| Jul 31, 2019 | 119.88 Mn |
| Apr 30, 2019 | 118.13 Mn |
| Jan 31, 2019 | 126.53 Mn |
| Oct 31, 2018 | 132.56 Mn |
| Jul 31, 2018 | 57.62 Mn |
| Apr 30, 2018 | 61.39 Mn |
| Jan 31, 2018 | 66.66 Mn |
| Oct 31, 2017 | 34.74 Mn |
| Jul 31, 2017 | 30.78 Mn |
| Apr 30, 2017 | 34.35 Mn |
| Jan 31, 2017 | 38.05 Mn |
| Mar 31, 2016 | 49.68 Mn |
| Dec 31, 2015 | 56.79 Mn |
| Sep 30, 2015 | 62.08 Mn |
| Jun 30, 2015 | 67.60 Mn |
| Mar 31, 2015 | 7.71 Mn |
| Dec 31, 2014 | 6.64 Mn |